Compass Pathways is a public biotechnology company developing investigational psilocybin-based therapies and related care models for treatment-resistant depression and other mental-health conditions.
Citing the urgent unmet need for patients with advanced biliary tract cancer, Compass Therapeutics will continue to seek an approval path for its drug after the FDA recommended the biotech conduct a new clinical study.
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training — latest FDA regulatory news.
BioSpace reports: Compass’ psilocybin depression drug works for the long haul.
Chief Executive Officer